A carregar...
Realized and Projected Cost-Savings from the Introduction of Generic Imatinib Through Formulary Management in Patients with Chronic Myelogenous Leukemia
BACKGROUND: Imatinib, a first-generation tyrosine kinase inhibitor (TKI), and the newer second-generation TKIs have dramatically improved outcomes for patients with chronic myelogenous leukemia (CML). A previous model estimated the potential cost-savings over the next 2 years after the loss of paten...
Na minha lista:
| Publicado no: | Am Health Drug Benefits |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Engage Healthcare Communications, LLC
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6996618/ https://ncbi.nlm.nih.gov/pubmed/32055281 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|